Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jordanian FDA Drug Director Laila Jarrar On Collaborations With Korean Regulators To Spur Biologics Growth - An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

The fast-growing pharmaceutical market in the Middle East has seen an increasing demand for regulators to step up to new challenges such as biologics and biosimilars, and to answer the call they are enhancing collaborations with leading health authorities around the world.

You may also be interested in...



Saudi FDA Licensing Director Hajed Hashan On CTD And Drug Licensing: An Interview With PharmAsia News

As licensing director of the Saudi Food and Drug Administration, Dr. Hajed Hashan plays a key role in the largest pharmaceutical market in the Gulf region and one of the largest in the Middle East. Established in 2004, SFDA has recently initiated several changes aimed at standardizing its filing and registration process and making SFDA the leading regional health regulator. Along the sidelines of the Drug Information Association's Middle East Regulatory Conference in Amman, Jordan, Hashan spoke to PharmAsia News about some of SFDA's newest initiatives, regulatory challenges and the pharmaceutical environment in the kingdom.

Saudi FDA Licensing Director Hajed Hashan On CTD And Drug Licensing: An Interview With PharmAsia News

As licensing director of the Saudi Food and Drug Administration, Dr. Hajed Hashan plays a key role in the largest pharmaceutical market in the Gulf region and one of the largest in the Middle East. Established in 2004, SFDA has recently initiated several changes aimed at standardizing its filing and registration process and making SFDA the leading regional health regulator. Along the sidelines of the Drug Information Association's Middle East Regulatory Conference in Amman, Jordan, Hashan spoke to PharmAsia News about some of SFDA's newest initiatives, regulatory challenges and the pharmaceutical environment in the kingdom.

Jordanian Drug Maker Buys Baxter Injectable Business, Becomes Second Largest In U.S.

Fast-growing Jordanian drug maker Hikma will acquire Baxter Healthcare's U.S. generic injectables business for $112 million. The acquisition doubles Hikma's injectables business and bolsters the company to the No. 2 position in the U.S. market with a projected market share of more than 15 percent. It also solidifies Hikma's leading position in the Middle East and North African (MENA) market, one of the rapidly growing "pharmerging" markets in the world

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel